Compass Pathways plc, a biotechnology company focused on mental health innovations, announced the appointment of Justin Gover to its Board of Directors. Gover, who has over 25 years of biopharmaceutical industry experience and previously led GW Pharmaceuticals, joins as the company progresses towards potential approval and commercialization of their treatment for treatment-resistant depression. Dr. Linda McGoldrick will retire from the Board at the end of October after more than five years of service.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.